Judge Compels Glaxo CEO To Answer Questions In Challenge To AZT Patent
A California federal court has ruled that GlaxoSmithKline's chief executive officer must answer further questions in a deposition in a challenge to its patent rights to AZT (Retrovir), the first AIDS...To view the full article, register now.
Already a subscriber? Click here to view full article